Radiolabeled TSPO Targeted Molecular Probe in Alzheimer's Disease.
NCT07105956 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 8
Last updated 2025-08-06
Summary
Evaluate the clinical application value of the novel radiolabeled TSPO-targeted molecular probe Gallium \[68Ga\]-DOTA-HK-011 in neuroinflammation imaging of Alzheimer's disease.
Conditions
- Alzheimer's Disease (AD)
Sponsors & Collaborators
-
Nanjing First Hospital, Nanjing Medical University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-09-01
- Primary Completion
- 2026-08-31
- Completion
- 2026-08-31
Countries
- China
Study Locations
More Related Trials
-
[18F]SF12051 for Imaging the 18-kDa Translocator Protein (TSPO) in Brain and Whole Body of Healthy Subjects
NCT05564429 ·Status: TERMINATED ·Phase: PHASE1
-
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
NCT05260151 ·Status: UNKNOWN
-
Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
NCT02836327 ·Status: UNKNOWN
-
New Biomarker for Alzheimer's Disease Diagnostic
NCT01315639 ·Status: COMPLETED ·Phase: NA
-
Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative Dementia
NCT06534658 ·Status: RECRUITING
-
Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
NCT00657813 ·Status: TERMINATED ·Phase: PHASE1
-
Cerebellar ITBS Mode Transcranial Magnetic Stimulation for the Treatment of Alzheimer's Disease
NCT06379100 ·Status: COMPLETED ·Phase: NA
-
Use of in Vivo 3T MR to Characterize Carotid Plaque in Patients and Correlate MR Findings With Symptoms
NCT02335567 ·Status: COMPLETED
-
A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).
NCT00978536 ·Status: TERMINATED ·Phase: NA
-
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity
NCT01078636 ·Status: COMPLETED
-
Multi-modality MRI Study on Prediction for Mild Cognitive Impairment Conversion
NCT02353884 ·Status: COMPLETED
-
A Composite MR Neuroimaging Marker for Alzheimer's Disease
NCT01615666 ·Status: WITHDRAWN
-
The GBA Multimodal Study in Parkinson's Disease
NCT04101968 ·Status: RECRUITING
-
Application of Multi-probe PET/MR Imaging in the Diagnosis and Evaluation of Alzheimer's Disease
NCT05003830 ·Status: UNKNOWN
-
Multimodal Markers of Neurodegenerative Disorders at Presymptomatic Stages
NCT06516016 ·Status: NOT_YET_RECRUITING
-
Tau PET Imaging With 18F-T807(AV1451) in Neurodegenerative Disorders
NCT04926259 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
The Influence of Sequential Tau Protein and Amyloid Plaque Imaging Changes on Stroke Prognosis and Cognitive Outcome
NCT04572477 ·Status: UNKNOWN ·Phase: PHASE2
-
Multimodal Biomarkers for Diagnosis and Prognosis in VCI
NCT04604600 ·Status: UNKNOWN ·Phase: PHASE3
-
Positron Emission Tomography of Amyloid in Alzheimer's Disease
NCT00205621 ·Status: SUSPENDED ·Phase: PHASE1
-
Multimodal Biomarkers for Diagnosis and Prognosis in CAA
NCT03969732 ·Status: UNKNOWN ·Phase: PHASE3
-
Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease
NCT04057807 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Targeted Translocator Protein PET Imaging Evaluate Neuroinflammation of the Chronic Pain Patients
NCT06701734 ·Status: NOT_YET_RECRUITING
-
Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects
NCT04141150 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
NCT02531360 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
NCT05456503 ·Status: RECRUITING ·Phase: PHASE3